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We have isolated and  characterized the 5”flanking re- 
gion of the gene for  human  ferrochelatase  (HFC), the 
last enzyme of the heme biosynthetic pathway. The 
proximal promoter of the gene is contained within a 
region that  structurally  resembles  a CpG island  and is 
devoid  of  general cis elements such as TATA and CAAT 
boxes.  Recognition sites for the ubiquitous Spl family of 
transcription  factors, as well as for the erythroid- 
specific truns-acting factors W-E2 and GATA-1 were 
found,  and  binding  of  regulatory  proteins to these ele- 
ments  was  analyzed  by  in  vitro  DNase I protection as- 
says. The contribution of the various cis elements to 
both  ubiquitous  and  erythroid  preferential  expression 
of the HFC gene  was assessed by using transient  trans- 
fection assays.  These  showed  that  a  minimal Sp -driven 
promoter  devoid of the upstream  erythroid-specific ele- 
ments  was sufficient for  erythroid  preferential  expres- 
sion of the HFC gene. However,  elimination  of  a  repres- 
sor  sequence lying between  the  minimal  promoter  and 
the erythroid-specific  elements resulted in high levels of 
expression in human erythroleukemic K562 cells only 
when the cis elements recognized by  GATA-1 and NF-E2 
were  present, suggesting that the activity of these fac- 
tors is regulated by a  downstream  repressor in eryth- 
roid cells. 
Ferrochelatase (protoheme ferro-lyase, EC 4. 99. 1.11, the 
last enzyme of the  heme biosynthetic  pathway, catalyzes  the 
chelation of ferrous iron and protoporphyrin to form heme. 
Isolation of cDNAs from  mouse and  man has revealed the  pres- 
ence of two mRNAs that differ in  their 3’ end (1, 2). In both 
species, the mRNAs are  transcribed from a single gene, which 
in  man is located  on chromosome 18q21.3 (3). The  human  gene 
has  also  been isolated and  has been  shown to be composed of 11 
exons spanning over 45 kilobases  (4). Several  mutations  in  the 
ferrochelatase  gene  have been associated  with protoporphyria 
(3, 5-13), a disease which is characterized enzymatically by a 
decrease in the  ferrochelatase  activity  leading  to  the accumu- 
lation of its  substrate  protoporphyrin (14-17). 
Unlike  the globin genes,  enzymes  participating  in  the  heme 
biosynthetic pathway must be expressed in all cell types to 
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supply  the  heme  required as a cofactor for the  respiratory cy- 
tochromes. Nonetheless,  the  greatest  need for heme  is  during 
erythropoiesis, when large amounts of hemoglobin are pro- 
duced at the terminal stages of red cell differentiation. Re- 
cently, the  transcriptional  regulation of two of the  genes coding 
for enzymes in  the  heme biosynthetic pathway  has been stud- 
ied. These are  the 5-aminolevulinate synthase genes (ALAS)’ 
and  the porphobilinogen deaminase gene (PBGD). These genes 
differ in  the way in which they solve their problem of sustain- 
ing  both housekeeping and  erythroid  preferential expression. 
In  the case of ALAS, two different genes encode two ALAS 
isozymes, one  expressed  ubiquitously  while the expression of 
the  other  is  restricted exclusively to  erythroid  tissue (18, 19). 
On  the  other  hand, two different PBGD mRNAs, having a spe- 
cific first exon and 13 common exons, arise from a  single  gene. 
This  is achieved by differential  usage of two different  promot- 
ers, one of them erythroid-specific, within  the  same  gene (20, 
21). The erythroid-specific promoters of both genes  have been 
shown  to  contain cis elements recognized by erythroid-specific 
truns-acting factors (22-24). 
Human  ferrochelatase is transcribed from a single  promoter 
in  both  erythroid  and non-erythroid cells (6). In  this  study we 
show that this  promoter  lacks both apparent TATA and CAAT 
boxes, and its proximal region is contained within a region 
showing characteristics of CpG islands. The HFC gene pro- 
moter  contains cis elements recognized by the  erythroid- 
specific factors  NF-E2  and GATA-1 and by the  Spl  family of 
transcription factors. The  interplay between these cis elements 
and a negative  regulatory region may  determine  either house- 
keeping or tissue  preferential expression of the  HFC gene. 
MATERIALS AND METHODS 
Cell CultureAurkat leukemic T cell line,  human  K562,  and  murine 
MEL erythroleukemia  cell  ines  were  grown  in  RPMI  1640  (Life 
Technologies, Inc.)  supplemented  with 10% fetal  bovine serum (Gemini 
Bioproducts, Calabasas, CA), 2 mM L-glutamine (Life Technologies, 
Inc.),  and 1% penicillin-streptomycin  mixture  (Life  Technologies,  Inc.). 
Human  hepatoma  Hep G2 cells  were cultured  in Earle’s  minimal es- 
sential medium (Life Technologies, Inc.) with the same supplements 
described above. All cells were kept at 37 “C in an humidified  atmo- 
sphere  containing 5% CO,. Drosophila melanogaster Schneider L2 cells 
were cultured in Drosophila Cells Medium (Life Technologies, Inc.) 
supplemented  with 12% fetal bovine  serum at room temperature. 
Isolation and  Analysis of Genomic Sequences of the Human Ferro- 
chelatase Gene-A human  genomic library  constructed  from DNA iso- 
lated from the HUT-78 T cell  line into the A-FIX bacteriophage  vector 
(Stratagene, La Jolla, CA) was generously provided by Dr. J. M. 
Redondo (Hospital de la Princesa,  Madrid, Spain). 1.5 x IO6 bacterio- 
phage  plaques  were  screened by using standard procedures (25)  with a 
0.4-kb BemHI 5’ end  probe  isolated  from the human cDNA (1,3). Eight 
independent overlapping clones were isolated and shown to contain 
most of the entire human  genomic  locus (4).  Sequential  hybridization 
The abbreviations used are: A L A S ,  5-aminolevulinate synthase; 
HFC, human ferrochelatase; PBGD, porphobilinogen deaminase; kb, 
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performed with 32P-labeled  oligonucleotides spanning the whole  coding 
region  allowed the mapping and identification of the clones by using 
standard filter hybridization techniques. Human sequences were sub- 
cloned into pBluescript (Stratagene) for further sequencing with Seque- 
nase (United States Biochemical  Corp, Cleveland, OH). Sequences were 
analyzed for their G+C content by using the University of Wisconsin 
Genetic Computer Group program package according to Gardiner- 
Garden and Frommer (26). 
Plasmids-To assay for promoter activity, a 4-kilobase PstI-Sac11 
(+55) fragment was  subcloned into the promoterless plasmid  P19-luc 
containing the Photynus pyralis luciferase gene as a reporter (27). De- 
letions were  performed  from the XbaI restriction site (-1.1 kb) by using 
the Exonuclease 111-Mung Bean nuclease deletion kit (Stratagene). As 
controls, the plasmid  pSV2luc, containing the SV40 early promoter and 
enhancer linked to the luciferase gene (28) and the pCMVp, containing 
the cytomegalovirus immediate early promoter and enhancer linked to 
the p-galactosidase gene  (Clontech Laboratories, Palo Alto,  CA),  were 
used. The Spl expression vectors pPacSpl and pPacl68C, which  con- 
tains the Spl DNA-binding  domain but not the transactivation domain, 
have been previously described (29). Sequencing analysis was per- 
formed on denatured double-stranded templates (30) by using Seque- 
nasem (USB). 
Dansient Dansfection and Reporter  Assays-Plasmid DNA used for 
transfections was isolated essentially as described (30) and then puri- 
fied once through a CsCl gradient. Transfections were  performed either 
with Lipofectin (Life Technologies, Inc.) or by electroporation as de- 
scribed (31, 32). After 48-72 h, cells were harvested, and luciferase 
activity was measured from the total cell extract (28) in  a Monolight 
2001 luminometer (Analytical Luminiscence Laboratories, San Diego, 
CA). Schneider L2 cells were transfected with Lipofectin under the 
same conditions  described earlier. After 48 h, whole  cell extracts were 
prepared and assayed for luciferase activity. Relative luciferase activity 
was  normalized  according to the protein concentration of the extracts, 
the fold induction over the luciferase activity obtained upon transfec- 
tion with the promoterless construct P19-luc  was calculated, and pro- 
moter activity was expressed in comparison to the values obtained upon 
transfection of the pSV2L construct. 
Nuclear Extracts, Electrophoretic  Mobility Shift, and DNase I Pro- 
tection  Assays-Nuclear extracts were obtained as described  previously 
(33). Purified Spl was purchased from Promega Biotech  (Madison,  WI). 
Escherichia coli-expressed human cJun was kindly provided by Drs. 
Tiliang-Den and Michael Karin (University of California, San Diego, 
CA). Purified murine GATA-1 was the generous gift of Dr. Beverly 
Emerson (The Salk  Institute, La Jolla, CA). The procedures followed for 
electrophoretic mobility shift assays and DNase I protection analysis 
using linear templates have been  described (33,34). The probes used in 
the electrophoretic mobility shift assays were double-stranded oligonu- 
cleotides containing either  the consensus NF-E2-binding site (TCC  TCC 
AGT  GAC  TCA  GCA  CAG  GTT  CC) or a  mutant version that binds AP-1 
but not NF-E2 (TCC TCC AGT GAC TCA GAA CAG GTT CC) (35). 
Recessive 3’ ends were  filled-in with [a-32PldCTP (3000  Ci/mmol) and 
the rest of the cold deoxynucleotides triphosphate by using murine 
leukemia virus reverse transcriptase  (Stratagene). 
For DNase I protection analysis using single end-labeled fragments, 
the radiolabeled fragments were separated through electrophoresis in 
1.5% agarose-TAE (Tris acetate ethylenediaminetetraacetate) gels and 
isolated with DE81 paper (Whatman Intl. Ltd., Maidstone, United 
Kingdom) (36). DNase I protection assays using intact plasmid DNA 
templates were  performed as described (36). 
RESULTS 
Primary Structure of the 5“Flanking Region of the Human 
Ferrochelatase Gene-Genomic clones containing the HFC  gene 
5”flanking region  were isolated from a  human genomic library 
constructed in  the bacteriophage vector A-FIX (Stratagene) by 
using a 5’ BamHI 0.4-kb probe from the HFC cDNA (3). A 
restriction enzyme map encompassing the 5”flanking region, 
exons 1 and 2, intron 1,  and part of intron 2 is shown in Fig. lA. 
Exons  were  located by sequential hybridization with oligonu- 
cleotides complementary to the cDNA, and their intron-exon 
junctions were  confirmed by  DNA sequence analysis. The tran- 
scription start site of the gene has been determined by others 
(4) ,  and  the proposed  location is indicated (Fig. 1B ). Analysis of 
the primary structure of the 5”flanking region reveals the ab- 
sence of both canonical TATA and CAAT boxes, as well as  a 
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region.A, restriction map of a 17-kb DNAfragment containing the first 
FIG. 1. Structure  of the human ferrochelatase  gene  5’-flanking 
two exons of the gene and adjacent sequences. Boxes represent the 
exons, and the shaded area corresponds to the  5’-untranslated region. 
Relevant restriction endonuclease sites are indicated: E ,  BamHI; E, 
EcoRI; K,  KpnI; N, NotI; Sm, SmaI; Ss, SacI;Xb, XbaI. The A-FIX  clones 
containing the genomic sequences are shown under the map. B, DNA 
sequence of the HFC  gene  promoter. The proposed transcriptional start 
site  is at +l. Consensus binding sites for Spl, GATA-1, and NF-E2/AP-1 
are indicated. 
consensus initiator element (37) around the transcription start 
site. However, a high degree of homology was found between 
this region and the transcription initiation region of the c-ets 2 
protooncogene (38). Sequence  comparison analysis revealed the 
presence of several putative recognition sites for the ubiquitous 
transcription factor Spl (-119 to -112, and -77 to -70 on the 
non-coding strand) (39), and for the erythroid-specific factors 
NF-E2 (-280 to -270) (35), and GATA-1(-318 to -322,  on the 
non-coding strand) (40) (Fig. lB). 
In addition, the region spanning from -160 to +400 is com- 
posed of S O %  C+G nucleotides. The ratio of the observed-to- 
expected of the CpG dinucleotide was 0.8 within this region, 
which fulfills the definition of a CpG island (41). 
A Minimal  -150-Base Pair Promoter Fragment Is Sufficient 
to Confer Erythroid Preferential Expression of the Human Fer- 
rochelatase Gene-To demonstrate that  the 5‘ end of the HFC 
gene contains promoter sequences which are active in eukary- 
otic cells, several fragments of the 5”flanking region were 
cloned to drive the expression of the P. pyralis luciferase re- 
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FIG. 2. Activity of the HFC gene promoter  in both erythroid 
and non-erythroid cells. A 4-kb fragment of the  human ferroche- 
latase  gene  with  its 3' end a t  +55 was subcloned into  the vector pl9luc 
(27) (-4.0-luc). Deletions were performed in this construct by using 
restriction  sitesXhaI  (-1.1-lucj  and  SmaI  (-0.15-luc).  These  constructs 
and SV-luc as  a control were  transiently  transfected  into Jurkat (T cell 
line),  Hep G2 (hepatome  derived), K562 (embryonic  erythroid cell line), 
and  MEL  (adult  erythroid cell line) by using Lipofectin at a  ratio of 5 pg 
of DNA/10 pg of Lipofectid5 x IO5 cells. After 48 h cell extracts  were 
assayed for luciferase activity. Data  shown  are  representative of two 
independent  experiments performed in  duplicate. 
porter gene. Three promoter constructs  with  the  same  3'  end 
(+55) and 5' ends of different  lengths (-4.0, -1.1, and -0.15 kb) 
were tested for activity by performing transient  transfections 
into cells of either  the  erythroid  lineage (K562 and MEL) or 
other origin (Hep G2 and  Jurkat). As shown  (Fig. 21, all con- 
structs  are efficiently transcribed  in  all cell lines analyzed. The 
activity of the  transiently  transfected promoter is consistently 
higher (3-4-fold) in  erythroid cells in  all of the  reporter gene 
plasmids  tested.  The -1.1-kb promoter fragment  is  less active 
than  the -4.0 kg or -150 constructs  in  erythroid cells, which 
might reflect  negative regulatory  elements  within  the -1.1-kb 
promoter fragment. 
The 5' end of the  HFC gene has a  high G+C content,  and  the 
presence of strong secondary structures  at  the 5' end of the 
HFC gene prevented the analysis of the minimal -150 pro- 
moter  with  routine  DNase I footprinting  techniques.  For  that 
purpose, DNase I footprinting analysis  was performed on su- 
percoiled templates  with  the single-sided  polymerase chain  re- 
action method as described (36). As shown in Fig. 3, nuclear 
proteins from erythroid (K562) cells form multiple DNA-bind- 
ing complexes in  the proximal  promoter region when compared 
to nuclear protein extracts of Hep G2 cells. Nuclear protein 
extracts  obtained from other non-erythroid cells such  as  HeLa 
or Jurkat  behave  similarly to  the  Hep G2 extracts  (data  not 
shown). The sites already defined as Spl-binding sites (see 
below) had similar protection patterns with all the nuclear 
extracts analyzed. Interestingly,  the sequence 3"GCGAT- 
GGG-5' (+3  to +10 on the non-coding strand) close to  the pro- 
posed transcription  start  site,  is protected from DNase I diges- 
tion by K562 nuclear proteins. This sequence has been reported 
to be a potential low-affinity recognition site for the  erythroid- 
specific protein GATA-1 (42, 43). However, we were unable  to 
reproduce the same protection pattern with purified murine 
GATA-1 (data  not shown). 
Dunscription Factor Sp l   and lo r  Related Factors Bind to 
Atypical Sites on the HFC Gene Proximal Promoter-The mini- 
mal promoter  shown to  contain  maximal activity in  transient 
transfection assays (-0.15 kb) also contains two canonical GC 
boxes (at -119 to -112, and -77 to -701, which have been 
described as  putative  binding  sites for the  transcription factor 
S p l  (39). However, DNase I footprinting analysis (Fig. 4A) 
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of the HFC gene. The  HFC  promoter  fragment from -367 to +55 was 
FIG. 3. Binding of nuclear   proteins  to the proximal promoter 
originated by exonuclease 111-mung bean  nuclease  deletions from the 
-1.1-kb construct. Twenty fmol of supercoiled plasmid were incubated 
with 20 pg of nuclear  proteins ( N E )  from either K562 or Hep G2 cells 
and  subjected  to  DNase I digestion as indicated.  The  resulting  digestion 
products  were  detected by primer  extension from the  reverse  primer 
using Taq polymerase. A sequence  ladder  was  originated by using  the 
same  plasmid  and  primer. 
shows that  nuclear  proteins do not bind to  the canonical GC 
boxes but  instead  to  nearby  elements at -120 and -100. When 
the protection pattern of nuclear  proteins from erythroid cells 
(K562) is compared with  that of non-erythroid cells (HepGB), 
the DNase I protection pattern of the  distal  site (-120) is dif- 
ferent (Fig. 4A). To test whether Sp l  actually binds to the 
putative Sp l  sites, DNase  I  protection assays were performed 
with highly purified human Spl instead of nuclear protein 
extracts. Both the -100 and -120 binding  sites  that  are pro- 
tected by nuclear  extracts  are also recognized by purified Spl  
(Fig. 4B). The affinity of Sp l  toward the proximal site  is re- 
markably  higher  than for the  distal  site (Fig. 4B). Binding of 
trans-acting factors to this region is  summarized  in Fig. 4C. 
Some protection seems to take place around -70, but  this  was 
not consistently observed and protection was not enhanced 
with increasing  amounts of Spl.  
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FIG. 4. Transcription factor Spl binds functionally to the HFC gene promoter. A and B, binding of nuclear  proteins  to the -200 to -60 
region of the HFC gene. A BamHI (-260)  to BglI (-47) fragment  was  labeled by fill-in reaction at   the BanHI  site  and  was subjected to DNase I 
digestion  after  incubation  with  either 20 pg of nuclear  proteins from K562 or HepG2 cells (A), or  with  increasing  amounts of purified human  Spl 
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The functional significance of these Spl recognition sites was 
tested in a heterologous system provided by the Drosophila cell 
line Schneider SL2. Insect cells lack endogenous Spl activity, 
which can be  provided  upon transfection of an  Spl expression 
vector. As shown (Fig. 401, transcription from both the -1.1-kb 
and the minimal -0.15-kb promoters is stimulated by  co- 
expression with full-length Spl (pPacSp1) but not with a trun- 
cated form of Spl (pPacl68C) lacking the trans-activation do- 
mains  A and B. 
The Erythroid-specific Factors NF-E2 and GATA-1 Bind to 
the 5’-Flanking Region of the Human Ferrochelatase Gene- 
DNA sequence comparison analysis of the 5”flanking region of 
the HFC  gene revealed the presence of consensus cis elements 
that could be recognized by the erythroid-specific transcription 
factors GATA-1 and NF-E2 (-322 to -318 on the non-coding 
strand,  and -280 to -270, respectively). The NF-E2 recognition 
site is also recognized by the ubiquitous transcription factor 
AP-1 (44). In vitro DNase I footprinting analysis indicate that 
nuclear proteins from erythroid cells  effectively protects from 
DNase I digestion both of these proposed cis elements (Fig. 5A 1. 
In contrast,  nuclear proteins from non-erythroid Hep G2 cells 
do not protect the GATA-1 recognition site but display binding 
at  the NF-E2/AP-1 consensus cis-element. 
The nature of the proteins binding to  the NF-E2IAP-1 and 
GATA sites on the HFC gene promoter was further analyzed. 
First, electrophoretic mobility shift assays were performed to 
validate the binding patterns of oligonucleotides containing 
consensus NF-E2 and/or AP-1 sites with nuclear protein ex- 
tracts (Fig. 5B).  The oligonucleotide probe NF-E2 (E21 binds 
both NF-E2 and AP-1, while the  mutant NF-E2 probe (mE2) 
contains a  mutation that prevents binding of NF-E2 but  still 
allows binding ofAP-l(35,44). Based on the competition profile 
shown in Fig. 5B, and experiments performed by others  (35), 
putative AP-1- and NF-E2-binding complexes are indicated by 
arrows. The  fastest  migrating complex  could  be  competed with 
increasing amounts of nonspecific DNA (poly(d1-dC)) so was 
assumed to be a nonspecific DNA binding activity. 
Once the binding pattern of these oligonucleotides was es- 
tablished,  they were used as competitors in DNase I footprint- 
ing experiments with K562 extracts and the HFC 5’ region. 
These show that addition of 100-fold molar excess of the NF-E2 
competitor oligonucleotide to the binding reaction prevents 
binding of nuclear proteins to the NF-E2/AP-1 site of the HFC 
promoter (-280 to -270) (Fig. 5C) .  However, binding of NF-E2 
to  the NF-E2/AP-l site is not  competed by the  mutant NF-E2 
oligonucleotide,  which removes all of the AP-1 binding activity 
from the extract (Fig. 5C; see also Fig. 5B). 
A  similar set of reactions showed that even 100-fold molar 
excess of an oligonucleotide representing the GATA-1 recogni- 
tion site from the PBGD gene (23) was unable to compete  for 
binding of nuclear proteins to the consensus GATA-1 site on the 
HFC gene promoter (Fig. 5C) .  Nevertheless, highly purified 
murine GATA-1 binds specifically to  the putative GATA-1 site 
on the HFC gene promoter (-322 to  -318) (Fig. 6A). 
As NF-E2 appeared to be binding preferentially to the NF-E2 
site on the HFC gene promoter, binding of human AP-1 to the 
site was assessed by using E. coli-expressed c-Jun (Fig. 6B). 
Binding assays were also performed in  the presence of murine 
GATA-1, showing that GATA-1 binding to its site does not affect 
the binding of c-Jun to its recognition site (Fig. 6C).  A  summary 
of these experiments is shown in Fig. 6D. 
Erythroid-specific Danscriptional Activation of the HFC 
Gene by NF-E2  and GATA-1 Is Controlled by a Repressor-The 
contribution of these erythroid-specific elements to the  tran- 
scriptional activity of the HFC  gene promoter was assessed by 
transient transfection assays. A construct containing both 
erythroid-specific modules (-367 to  +55) (-.367-luc) does not 
display higher activity than a construct devoid of these ele- 
ments (-150 to +55). DNase I footprinting analysis revealed a 
strong DNase I-hypersensitive site in uitro, upstream of the 
distal Spl site (Fig. 4A). This hypersensitive site is contained 
within an imperfect palindrome which resembles the binding 
site of a  strong stage-specific repressor of the transcription of 
the p-globin gene (45). Deletion of sequences from  -262  to  -150, 
which removes a region containing only this element (ABP) (see 
Fig. 7B), results in at  least a 6-7-fold increase of transcription 
in erythroid cells (K562) and  a 3-4-fold increase in  the T cell 
line Jurkat, while it has a smaller effect in  a hepatoma cell line 
(Hep G2) (Fig. 7). 
DISCUSSION 
We have isolated and analyzed the 5’-flanking region of the 
human gene for HFC, the  last enzyme of the heme biosynthetic 
pathway. Like other enzymes participating in this pathway, 
activity of ferrochelatase is required in all cell types in order to 
provide heme for respiratory cytochromes.  Additionally, there 
is a  greater demand for heme for the synthesis of hemoglobin 
during erythroid differentiation. Unlike other enzymes in- 
volved in heme synthesis,  human ferrochelatase was found to 
be transcribed from a single promoter in both erythroid and 
non-erythroid cells. Our analysis of the HFC gene reveals at  
least three possible, non-exclusive mechanisms by which tran- 
scription of the gene can be enhanced in erythroid cells. 1) The 
core minimal promoter contains non-canonical Spl sites that 
can be  recognized by different members of the  Spl family de- 
termining both ubiquitous and erythroid preferential expres- 
sion of the gene; 2) the 5”flanking region of the HFC gene 
promoter contains documented NF-E2 and GATA-1 sites, the 
activity of which might be modulated by a downstream repres- 
sor; and 3), the erythroid-specific elements could be also in- 
volved in  the recruitment of a  distal erythroid enhancer. 
Primary structure analysis of the HFC gene 5“flanking re- 
gion reveals a high G+C content and  the absence of both ca- 
nonical CAAT and TATA boxes. Furthermore, the CpG dinucle- 
otide content within a 0.6-kilobase fragment containing the 
proximal promoter, the first exon, and  part of the first  intron, is 
significantly greater than expected. This high CpG occurrence, 
accompanied by the presence of multiple recognition sites for 
the restriction endonucleases HpaII  and  HhaI,  and a single 
Not1 site, suggest that  the HFC gene 5”flanking region is a 
CpG island (41, 46). CpG islands  are considered to be regions 
not highly packed into chromatin, and therefore accessible to 
regulatory proteins (471, and are found to  be present in  the 
promoters of many housekeeping genes (26, 41). 
Sequence comparison analysis of the promoter region dem- 
onstrates  the presence of several canonical binding sites for the 
ubiquitous transcription factor Spl(-75 and -115) and for the 
erythroid-specific factors NF-E2 (-270 to -280) and GATA-1 
(-322 to  -318). Binding sites for Spl  are widely distributed in 
TATA-less GC-rich promoters (48) and have been  proposed to 
(B) .  The molar ratio of Spl versus DNA is indicated. C, summary of binding of trans-acting factors to  HFC gene (-160 to +lo). DNase I protected 
were transiently transfected with the -1.1-kb and -0.15-kb  promoter luciferase constructs, and  the promoterless vector  p19  Luc (27), along with 
regions are shown by boxes and hypersensitivity sites by arrows. D, trans-activation of the HFC  gene  promoter by Spl in Schneider SL2 cells.  Cells 
expression vectors containing either  a full-length ( p P u c S p l )  or a mutant  Spl protein lacking the trans-activation domains (pPacl68C), under the 
control of the actin 5C promoter. As a control, reporter constructs containing none,  one, or  two Spl sites linked to  a TATA-less promoter (63) were 
included. 












PROBE NF-E2 mNF-E2 
m m 




- E2 - E2 
m 














FIG. 5. The erythroid  factors NF-E2 and GATA-1 bind  to  the HFC gene promoter. A, DNase I footprinting analysis on a Sal1 (on pl9luc) 
to SmaI (-150) fragment of the HFC  gene. The non-coding strand was labeled at  the Sal1 site by fill-in reaction. After isolation, the probe  was 
subjected  to incubation with 20 pg of nuclear proteins from  K562  or  Hep  G2 cells  prior to DNase I digestion and analysis on a  denaturing 6% 
acrylamide gel. A sequence marker was generated by performing the purine sequencing reaction (64) on the same probe.  Approximate  location of 
nucleotides is shown  on the left. B,  characterization of NF-E2/AP-l binding activities in both erythroid and non-erythroid cells.  Five  pg of nuclear 
proteins isolated from either K562 or Hep G2 cells  were incubated with  "P-labeled  oligonucleotides containing either  the NF-E2 consensus binding 
site (E2) ,  or a mutant version of the previous, unable to  bind  NF-E2 (rnE2) (35,44). Competitions  were  performed by adding 100-fold  molar  excess 
of the same oligonucleotides  to the binding reactions as indicated. The putative AP-1- and NF-E2-binding  complexes are shown by arrows. C ,  DNase 
I footprinting analysis in the presence of cold competitor  oligonucleotides.  DNase I footprinting was  performed as described earlier except that 
100-fold molar  excess ofthe oligonucleotides  described  above, plus the PBGD  GATA-1 site (GT)  and a  mutant  variant unable to  bind  GATA-1 (mGT) 
(23), were  added  to the binding reactions prior to  DNase I digestion. 
functionally  compensate  for  the  absence of a canonical TATA 
box (49).  Transient  transfection  assays  demonstrate hat a pro- 
moter  fragment  spanning  from -150 to +55, that contains  the 
canonical Spl  si tes  but  not  the erythroid-specific cis elements, 
is  sufficient  to  drive  efficient  and  erythroid  preferential  expres- 
sion of the  luciferase  reporter  gene. In vitro DNase I footprint- 
ing  analysis  revealed  that  the  transcription  factor  Spl  binds  to 
two  non-canonical Spl  sites  outside  the  GC  boxes that are and 
structurally similar to other proposed S p l  recognition sites 
(50). These  elements  can  be  recognized  not  only  by  Spl  but  also 
by the  products of genes that share a high  degree of homology 
wi th   Spl  (51-54). The distinct binding pattern observed be- 
tween  erythroid  and  non-erythroid  extracts  and  purified  Spl 
suggest that different  members of t h e   S p l  family  might  bind  to 
these elements with varying affinities. DNase I footprinting 
analysis  revealed  that  multiple  factors  bind  preferentially  to 
the  proximal  promoter  region  when  erythroid  nuclear  proteins 
extracts  were  used. It is  tempting  to  speculate that the  binding 
of different S p l  family members, like the erythroid-specific 
Kriippel-like  factor ( E U F )  (54), recognizing the CACCC motif 
present in the promoter of certain erythroid-specific genes, 
could affect the  binding of factors to the proximal promoter 
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FIG. 6. The transcription factors GATA-1 and c-Jun bind to the HFC promoter. DNase I footprinting  analysis performed with  affinity 
purified murine GATA-1 (A) and E. coli-expressed human c-Jun ( B ) ,  or both GATA-1 and c J u n  (C) added as indicated  in  the figure. D, summary 
of binding  results from DNase I footprinting  using  nuclear  extracts  and  recombinant  proteins. 
region and explain the preferential  expression of this  minimal to their cognate elements in vitro. Although the NF-E2 site 
promoter in  erythroid cells. could be recognized by AP-1, as shown by others (44), NF-E2 
Upstream from the minimal promoter, two erythroid-specific appeared  to bind  preferentially to  its  site  in erythroid  extracts, 
cis elements for the NF-E2 and GATA-1 transcription factors even when the  total AP-1 binding activity was shown to be 
were found by sequence homology. The binding of nuclear pro- much higher in mobility shift assays. The preferential  binding 
teins  to  these  putative  elements  was as essed by DNase I foot- of NF-E2 to  the HFC  gene  promoter is not due to exclusion of 
printing  analysis, revealing that both NF-E2 and GATA-1 bind AP-1  binding by  GATA-1, since affinity-purified GATA-1 did not 
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FIG. 7. Activity of the  erythroid-specific cis elements  in  the 
HFC gene  promoter. A, the  internal deletion ABP was tested and 
compared to other constructs in K-562, the T cell line Jurkat, and  the 
hepatoma cell line Hep G2. Results shown are representative of at least 
two independent experiments performed in duplicate. The constructs 
used in A are depicted in B. 
exclude the binding of Jun/A€"l to the NF-E2-binding site. 
Thus,  this  site  might  represent a higher affinity  binding site for 
NF-E2 although  the  participation of proteins other  than 
GATA-1, favoring  NF-E2  binding,  cannot be ruled out. Addi- 
tional protein  binding was detected as  an extended  footprint 
between the NF-E2 and GATA-1 sites.  This region was shown 
to be very  rich in A+T and  similar  to a low melting point region 
that  binds a single strand binding  protein which is a potent 
trans-activator  in  the c-myc gene  promoter (55) .  Mobility shift 
assays performed with a probe encompassing the whole pro- 
tected region (-330 to  -254) showed the binding of multiple 
proteins both in erythroid and non-erythroid cells (data not 
shown).  The region containing the erythroid-specific elements, 
however, did not  enhance  transcription of a reporter gene in 
transiently  transfected erythroid cells. Alternatively,  co-trans- 
fection of p45 NF-E2 (35) or GATA-1 (56) into Hep G2 cells did 
not account for a specific increase  in  transcription  (data  not 
shown) as reported by others  in co-transfected  non-erythroid 
cells (57,58). The lack of function of these  elements  in  transient 
transfection experiments might reflect either  the need for a 
distal erythroid-specific enhancer that could interact with 
GATA-1, as shown for the chicken P-globin gene (591, or that  an 
additional  element  within  the proximal promoter  controls the 
activity of the erythroid-specific elements. 
In vitro footprinting analysis performed with both  erythroid 
and non-erythroid nuclear protein extracts indicated the pres- 
ence of a strong hypersensitive site  (at -154) that  lies  within a
palindromic  sequence  between the NF-E2 site  and  the  distal 
Sp-1 site.  A similar sequence has  been shown in  the promoter of 
the chicken P-globin gene to bind PAL, a stage-specific repres- 
sor in  erythroid cells that is also present  in non-erythroid tis- 
sues (45). Deletion of the region in  the HFC gene promoter 
containing this palindrome conferred high tissue-specific ex- 
pression of a reporter gene in erythroid cells but not in a hepa- 
toma cell line. I t  is possible that  this level of expression in 
erythroid cells was achieved by allowing interactions between 
Spl  and/or related factors with GATA-1, as it has been de- 
scribed in both the PBGD erythroid  promoter  (60) and  in  the 
y-globin promoter (61). This could be an explanation in  the case 
of Jurkat cells, which contain GATA-3 (401, where some acti- 
vation is observed although  to a lesser  extent  than  that ob- 
tained  in K562 cells. This result obtained  with other lymphoid 
cells containing GATA factors would also suggest  that  the  in- 
teraction  with a erythroid-specific enhancer might also be re- 
quired for full expression of the gene in erythroid cells. Recent 
studies suggest that an additional regulatory step could be 
provided by the association of p45 NF-E2 with different mem- 
bers of the  muffamily of protooncogenes and/or the recognition 
of the NF-E2 site by inhibitory Maf dimers (62). 
From  our analyses we conclude that  the expression of the 
HFC  gene is  regulated at several levels. A CpG island embrac- 
ing  the 5"flanking region would allow the expression of a single 
minimal Spl-driven TATA-less promoter in all cell types by 
maintaining  an open chromatin  structure.  The recognition of 
the  Spl-binding  sites by either Sp l  or tissue-specific members 
of the family could determine a higher  rate of transcription  in 
erythroid cells uersus other cell types,  a process that may  also 
require  the presence of additional cell type-specific factors.  A 
ubiquitously  expressed repressor would then be responsible for 
the control of erythroid-specific trans-activators  that  are held 
in check upstream of the minimal promoter. This repressor only 
affects the activity of the  upstream binding  factors, while the 
activity of the  basal promoter remains unaffected. I t  is  tempt- 
ing  to  speculate  that,  like  the PAL protein present  in  the P- 
globin promoter, the activity of the repressor would be regu- 
lated  during erythroid  differentiation allowing high  expression 
of the HFC gene at the  terminal  stages of erythroid differen- 
tiation. 
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